Gaudium IVF and Women Health
CLOSEDIPO Date: 20 Feb - 24 Feb 2026
Listing Date: 27 Feb 2026
Price Range
Rs.75 - Rs.79
Issue Size
165 Cr
Min Investment
₹14,175
Lot Size
189 Shares
Schedule of Gaudium IVF and Women Health
Issue open date
20 Feb 2026
Issue close date
24 Feb 2026
UPI mandate deadline
24 Feb 2026 (5 PM)
Allotment finalization
25 Feb 2026
Share credit
26 Feb 2026
Listing date
27 Feb 2026
Mandate end date
11 Mar 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 165 Cr |
| Fresh Issue | 90 Cr |
| Offer for Sale | 75 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 25 Feb 2026 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 26 Feb 2026 | ₹79 | ₹0 | ₹79 (0%) |
| 23 Feb 2026 | ₹79 | ₹5 | ₹84 (6.33%) |
| 22 Feb 2026 | ₹79 | ₹9 | ₹88 (10.76%) |
| 21 Feb 2026 | ₹79 | ₹9 | ₹88 (10.76%) |
| 19 Feb 2026 | ₹79 | ₹9 | ₹88 (10.76%) |
| 18 Feb 2026 | ₹79 | ₹12 | ₹91 (15.19%) |
| 17 Feb 2026 | ₹79 | ₹15 | ₹94 (18.99%) |
| 16 Feb 2026 | ₹79 | ₹0 | ₹79 (0%) |
| 15 Feb 2026 | ₹79 | ₹0 | ₹79 (0%) |
| 14 Feb 2026 | ₹79 | ₹0 | ₹79 (0%) |
| 13 Feb 2026 | ₹79 | ₹0 | ₹79 (0%) |
Performance Gaudium IVF and Women Health
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.75 - Rs.79 | .... | ₹ 75.26 | -4.73% |
About Gaudium IVF and Women Health
Gaudium IVF and Women Health is engaged in providing in vitro fertilisation (IVF) treatment and reproductive healthcare services in India. The company offers fertility treatments, including IVF, intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), ovulation induction, frozen embryo transfer (FET), and cryopreservation for egg freezing. It also provides advanced sperm retrieval techniques for male infertility, laparoscopic and hysteroscopic surgeries, and preimplantation genetic testing (PGT). In addition, the company offers gynaecological care for conditions such as PCOD/PCOS and endometriosis, high-risk pregnancy management, nutritional counselling, and psychological support. Incorporated in 2015, the company operates through a hub-and-spoke model with a presence across India. It has seven main centres located in Delhi (Janakpuri and Kailash Colony), Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, supported by additional spoke centres through strategic alliances.
| Founded in | 2015 |
| Managing director | Dr Manika Khanna |
| Parent organization |
Financial Overview
Strengths
- Established IVF-focused brand founded by experienced specialist Dr. Manika Khanna.
- Pan-India presence with 30+ locations under a scalable hub-and-spoke model.
- Comprehensive fertility portfolio including IVF, ICSI and IUI treatments.
- Strong revenue growth and improving profitability in recent years.
- Positioned in a fast-growing Indian IVF market with high projected growth.
Risks
- High contingent liabilities relative to net worth.
- Exposure to operational and legal risks inherent in healthcare services.
- High employee attrition and dependence on skilled doctors and embryologists.
- Significant dependence on promoters for leadership and brand value.
- Past negative cash flows and rising borrowings are impacting financial flexibility
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 0.88 |
| Non-Institutional Investors (NIIs) | 10.94 |
| Retail Individual Investors (RIIs) | 6.66 |
| Employee | N/A |
| Total | 5.92 |